Mirum Pharmaceuticals (NASDAQ:MIRM) Rating Reiterated by HC Wainwright

Mirum Pharmaceuticals (NASDAQ:MIRM)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. They presently have a $66.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 80.33% from the company’s previous close.

Several other equities research analysts also recently issued reports on MIRM. Robert W. Baird raised their price objective on shares of Mirum Pharmaceuticals from $34.00 to $39.00 and gave the stock an “outperform” rating in a research report on Monday, June 17th. Baird R W upgraded shares of Mirum Pharmaceuticals to a “strong-buy” rating in a research report on Monday, June 17th. Cantor Fitzgerald restated an “overweight” rating and set a $40.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, May 9th. SVB Leerink decreased their target price on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating on the stock in a research note on Monday, March 18th. Finally, Citigroup boosted their target price on shares of Mirum Pharmaceuticals from $38.00 to $64.00 and gave the stock a “buy” rating in a research note on Tuesday, June 18th. Ten investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $53.64.

Mirum Pharmaceuticals Trading Up 1.9 %

Mirum Pharmaceuticals stock opened at $36.60 on Monday. Mirum Pharmaceuticals has a 52 week low of $23.14 and a 52 week high of $36.92. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.47 and a current ratio of 3.68. The stock has a market capitalization of $1.72 billion, a P/E ratio of -9.87 and a beta of 1.15. The stock has a 50-day simple moving average of $28.04 and a 200 day simple moving average of $27.37.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.14). Mirum Pharmaceuticals had a negative return on equity of 56.46% and a negative net margin of 69.67%. The business had revenue of $69.22 million for the quarter, compared to the consensus estimate of $69.71 million. Analysts expect that Mirum Pharmaceuticals will post -1.66 earnings per share for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, insider Pamela Vig sold 30,559 shares of the company’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $34.00, for a total transaction of $1,039,006.00. Following the sale, the insider now owns 27,406 shares of the company’s stock, valued at $931,804. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Saira Ramasastry sold 5,000 shares of the company’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $25.68, for a total transaction of $128,400.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Pamela Vig sold 30,559 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $34.00, for a total transaction of $1,039,006.00. Following the transaction, the insider now owns 27,406 shares in the company, valued at approximately $931,804. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 35,934 shares of company stock valued at $1,180,156. 22.87% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC boosted its holdings in Mirum Pharmaceuticals by 34.2% in the 1st quarter. Janus Henderson Group PLC now owns 2,767,210 shares of the company’s stock worth $69,470,000 after buying an additional 704,659 shares during the period. Silvercrest Asset Management Group LLC raised its position in shares of Mirum Pharmaceuticals by 64.6% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 162,817 shares of the company’s stock valued at $4,090,000 after buying an additional 63,871 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in Mirum Pharmaceuticals by 37.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,597,506 shares of the company’s stock worth $40,131,000 after purchasing an additional 432,824 shares during the period. Affinity Asset Advisors LLC raised its position in Mirum Pharmaceuticals by 220.0% in the 1st quarter. Affinity Asset Advisors LLC now owns 160,000 shares of the company’s stock worth $4,019,000 after purchasing an additional 110,000 shares during the period. Finally, William Blair Investment Management LLC raised its position in Mirum Pharmaceuticals by 0.9% in the 1st quarter. William Blair Investment Management LLC now owns 627,272 shares of the company’s stock worth $15,757,000 after purchasing an additional 5,494 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.